Skip to content
preclinicalLongevity & Cellular Health

Livagen

Also known as: Lys-Glu-Asp-Ala, KEDA tetrapeptide, Hepatic bioregulator

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator developed by Khavinson that targets liver tissue and DNA chromatin structure. Preclinical research demonstrates that Livagen can decondense heterochromatin in hepatocytes, potentially reactivating genes silenced by aging. It also modulates DNA methylation patterns in liver cells and has been studied for effects on liver function restoration in aged animal models.

3 cited references·3 researched benefits

Quick Answer

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator targeting liver tissue and chromatin remodeling. Research shows it can decondense heterochromatin in hepatocytes, potentially reactivating age-silenced genes. Part of the Khavinson bioregulator family, it represents a novel approach to liver health through epigenetic regulation rather than conventional pharmacology. Preclinical studies report improved liver function markers in aged animal models.

Key Facts

Mechanism
Livagen reportedly penetrates hepatocyte nuclear membranes and interacts with specific DNA sequences in liver-related genes. Electron microscopy studies show decondensation of heterochromatin regions in hepatocyte nuclei following Livagen treatment, suggesting epigenetic reactivation of silenced genes. The tetrapeptide may modulate histone modifications and DNA methylation patterns, shifting chromatin from closed (heterochromatin) to open (euchromatin) states in liver-specific genetic loci. This is proposed to restore youthful gene expression patterns in aging liver tissue.
Research Status
preclinical
Half-Life
~1–2 hours (estimated)
Molecular Formula
C₁₇H₃₀N₄O₈
Primary Use
Longevity & Cellular Health
Table of Contents

Benefits

  • Chromatin remodeling — decondenses heterochromatin in hepatocytes, potentially reactivating silenced genespreliminary
  • Liver function support — improves hepatic function markers in aged animal modelspreliminary
  • Epigenetic modulation — may favorably alter DNA methylation patterns in liver cellspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use only10–100 mcgVariablePreclinical research compound. No approved therapeutic dosing protocols.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Minimal adverse effects reported in preclinical studiesrare

Frequently Asked Questions

What evidence supports Livagen's chromatin effects?
Khavinson's group published electron microscopy studies showing visible heterochromatin decondensation in hepatocyte nuclei after Livagen treatment. Immunohistochemistry confirmed changes in histone modification patterns. While these morphological changes are documented, the functional consequences (which specific genes are reactivated and what clinical benefits result) are less well characterized. The chromatin remodeling mechanism is biologically plausible but requires more comprehensive genomic and proteomic validation.
Is Livagen available as a supplement?
Livagen is available from some peptide research suppliers but is not approved as a drug or dietary supplement by any regulatory agency. It has not undergone clinical trials in humans. The quality and purity of commercially available preparations is not verified by regulatory authorities. It should be considered an experimental research compound.

References

  1. 1
    Effect of Livagen peptide on chromatin structure in hepatocyte nuclei(2003)
  2. 2
    Short peptides modulate chromatin structure and gene expression in aging(2014)PubMed ↗
  3. 3
    Peptide bioregulators of gene expression: mechanisms and implications(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19